In August, OCRA hosted a listening session with the U.S. Food and Drug Administration (FDA) to better understand the impact of Covid-19 on clinical trial participation.
Watch the full FDA listening session in the video below.
Related Topics
OCRA-Funded Study Provides Clear New Evidence That Opportunistic Salpingectomy Drastically Reduces Risk of Ovarian Cancer
A new study published February 2 in JAMA Network Open provides the clearest evidence to date that opportunistic salpingectomy—the removal of the fallopian tubes during another gynecologic surgery—can dramatically reduce the risk of ovarian cancer. Led by a B.C.-based international collaboration known as the Ovarian Cancer Observatory, the study found that people who underwent opportunistic … Continued
(Webinar) – Ask the Experts: Gynecologic Sarcoma
Watch Now: Ask the Experts Webinar on Gynecologic Sarcoma On January 28, 2026, Ovarian Cancer Research Alliance (OCRA) hosted a live Ask the Experts: Gynecologic Sarcoma webinar with Matthew Hemming, MD, PhD. Moderated by Liza Lundgren, LCSW, OCRA’s Director of Education, this free session featured a live discussion and audience Q&A focused on gynecologic sarcoma research, … Continued
Action Alert: Urge Congress to Pass Final Bill on Cancer Research Funding and Early Detection
The Congressional Appropriations Committees have released a combined FY2026 Defense/Labor, Health and Human Services bill—and it includes several critical investments and policy provisions that would significantly strengthen the federal response to ovarian and other gynecologic cancers. This bill represents meaningful progress for our community, but it is not final. Congress must act swiftly to advance and … Continued